13 completed. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Completed 13 |
Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients Allopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention - Non-Alcoholic Fatty Liver Disease, Hyperuricemia | Phase 4 | Completed | Ain Shams University | 90 | 2022-01-01 | 2023-08-01 |
| Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia Aliskiren, Losartan - Hypertension,Essential, Hyperuricemia | Phase 4 | Completed | Hansung University | 66 | 2021-05-01 | 2024-12-05 |
| Nutraceutical on Hyperuricemia Uricemin, Placebo - Hyperuricemia | Phase 4 | Completed | University of Pavia | 116 | 2018-10-01 | 2020-11-10 |
| The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Allopurinol, Placebo - Chronic Gout, Hyperuricemia | Phase 4 | Completed | University of California, San Francisco | 27 | 2016-11-01 | 2020-06-23 |
| Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine - Gout | Phase 4 | Completed | Menarini International Operations Luxembourg SA | 196 | 2015-08-17 | 2019-06-21 |
| Zurig (Febuxostat) 40mg Efficacy and Safety Trial Febuxostat, Allopurinol - Hyperuricemia | Phase 4 | Completed | Getz Pharma | 50 | 2013-11-01 | 2019-08-01 |
| Prednisone for Heart Failure Patients With Hyperuricemia prednisone, allopurinol - Heart Failure, Hyperuricemia | Phase 4 | Completed | Hebei Medical University | 40 | 2009-02-01 | 2010-09-01 |
| Rasburicase in Tumor Lysis Syndrome Rasburicase - Hyperuricemia | Phase 4 | Completed | Sanofi | 33 | 2006-02-01 | 2009-09-25 |
| Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Rasburicase (SR29142) - Tumors, Hyperuricemia | Phase 4 | Completed | Sanofi | 94 | 2004-03-01 | 2009-03-30 |
| Treatment of Hyperuricemia in Patients With Heart Failure Benzbromarone (drug) - Heart Failure, Hyperuricemia | Phase 4 | Completed | Tottori University Hospital | 2004-01-01 | 2007-01-15 | |
| Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Rasburicase - Hyperuricemia | Phase 4 | Completed | Sanofi | 38 | 2003-03-01 | 2008-01-28 |
| Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. Perindopril, Hydrochlorothiazide, Estracomb TTS - Hypertension, Hyperuricemia | Phase 4 | Completed | Anna Posadzy-Małaczyńska | 180 | 2000-01-10 | 2019-04-22 |
| Allopurinol in Chronic Heart Failure Allopurinol, Placebo - Chronic Heart Failure, Hyperuricemia | Phase 4 | Completed | National Heart and Lung Institute | 16 | 2009-10-19 |
Heart Failure (2) · Hypertension (2) · Arthritis (1) · Cardiovascular Diseases (1) · Essential Hypertension (1) · Gout (1) · Inflammation (1) · Insulin Resistance (1) · Leukemia (1) · Lymphoma (1) · Neoplasms (1) · Non-alcoholic Fatty Liver Disease (1) · Recurrence (1) · Tumor Lysis Syndrome (1)
Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Cardiovascular Diseases (4) · Heart Diseases (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Vascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Crystal Arthropathies (1) · Digestive System Diseases (1) · Disease Attributes (1) · Fatty Liver (1) · Genetic Diseases, Inborn (1) · Glucose Metabolism Disorders (1) · Hematologic Diseases (1)
Allopurinol (6) · Febuxostat (3) · rasburicase (3) · Benzbromarone (1) · Colchicine (1) · Hydrochlorothiazide (1) · Losartan (1) · Naproxen (1) · Omeprazole (1) · Perindopril (1) · Pharmaceutical Preparations (1) · Prednisone (1) · Urate Oxidase (1) · aliskiren (1) · estradiol, norethindrone drug combination (1)
Sanofi (3) · Ain Shams University (1) · Anna Posadzy-Małaczyńska (1) · Getz Pharma (1) · Hansung University (1) · Hebei Medical University (1) · Menarini International Operations Luxembourg SA (1) · National Heart and Lung Institute (1) · Tottori University Hospital (1) · University of California, San Francisco (1) · University of Pavia (1)
China (2) · Italy (2) · United States (2) · Brazil (1) · Egypt (1) · Germany (1) · Japan (1) · Netherlands (1) · Pakistan (1) · Poland (1) · Romania (1) · Serbia (1) · South Korea (1) · United Kingdom (1)
Choe Seong Choon (1) · Claudio Borghi, Prof (1) · Jaderson Lima (1) · Kathleen Giacomini, PhD (1) · Kazuhide Ogino, MD (1) · Khalid Mahmood, FCPS (1) · Sarah Ma Zaki, Ass.Prof. (1)
PMID 12421831, PMID 15698861, PMID 18349746, PMID 19933411, PMID 21849262, PMID 23395281, PMID 31033362
2014 (1), R01DK103729 (1)